CD36 and macrophages in atherosclerosis

Cardiovascular Research

Volumn 75, Issue 3, 2007, Pages 468-477

  Collot Teixeira, Sophie ^a,b   Martin, Juliette ^a,b   McDermott Roe, Chris ^b   Poston, Robin ^a   McGregor, John Louis ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Atherosclerosis; CD36; Monocyte macrophages; OxLDL; Vascular

Indexed keywords

CD36 ANTIGEN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANTIGEN FUNCTION; ANTIGEN STRUCTURE; ATHEROSCLEROSIS; ENDOCYTOSIS; FOAM CELL; GENETIC TRANSCRIPTION; HYPERGLYCEMIA; INFLAMMATION; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

ANIMALS; ANTIGENS, CD36; ATHEROSCLEROSIS; BLOOD VESSELS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447509398     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.03.010     Document Type: Review

References (90)

1. Zhang Y., and Wahl L.M. Synergistic enhancement of cytokine-induced human monocyte matrix metalloproteinase-1 by C-reactive protein and oxidized LDL through differential regulation of monocyte chemotactic protein-1 and prostaglandin E2. J Leukoc Biol 79 (2006) 105-113
2. Talle M.A., Rao P.E., Westberg E., Allegar N., Makowski M., Mittler R.S., et al. Patterns of antigenic expression on human monocytes as defined by monoclonal antibodies. Cell Immunol 78 (1983) 83-99
3. Asch A.S., Barnwell J., Silverstein R.L., and Nachman R.L. Isolation of the thrombospondin membrane receptor. J Clin Invest 79 (1987) 1054-1061
4. McGregor J.L., Catimel B., Parmentier S., Clezardin P., Dechavanne M., and Leung L.L. Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation. J Biol Chem 264 (1989) 501-506
5. Swerlick R.A., Lee K.H., Wick T.M., and Lawley T.J. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 148 (1992) 78-83
6. Matsumoto K., Hirano K., Nozaki S., Takamoto A., Nishida M., Nakagawa-Toyama Y., et al. Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000) 1027-1032
7. Fernandez-Ruiz E., Armesilla A.L., Sanchez-Madrid F., and Vega M.A. Gene encoding the collagen type I and thrombospondin receptor CD36 is located on chromosome 7q11.2. Genomics 17 (1993) 759-761
8. Armesilla A.L., and Vega M.A. Structural organization of the gene for human CD36 glycoprotein. J Biol Chem 269 (1994) 18985-18991
9. Andersen M., Lenhard B., Whatling C., Eriksson P., and Odeberg J. Alternative promoter usage of the membrane glycoprotein CD36. BMC Mol Biol 7 (2006) 8
10. Noushmehr H., D'Amico E., Farilla L., Hui H., Wawrowsky K.A., Mlynarski W., et al. Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion. Diabetes 54 (2005) 472-481
11. Sato O., Kuriki C., Fukui Y., and Motojima K. Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands. J Biol Chem 277 (2002) 15703-15711
12. Zingg J.M., Ricciarelli R., Andorno E., and Azzi A. Novel 5′ exon of scavenger receptor CD36 is expressed in cultured human vascular smooth muscle cells and atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22 (2002) 412-417
13. Greenwalt D.E., Lipsky R.H., Ockenhouse C.F., Ikeda H., Tandon N.N., and Jamieson G.A. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood 80 (1992) 1105-1115
14. Puente Navazo M.D., Daviet L., Ninio E., and McGregor J.L. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL). Arterioscler Thromb Vasc Biol 16 (1996) 1033-1039
15. Ohgami N., Nagai R., Ikemoto M., Arai H., Kuniyasu A., Horiuchi S., et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 276 (2001) 3195-3202
16. Demers A., McNicoll N., Febbraio M., Servant M., Marleau S., Silverstein R., et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J 382 (2004) 417-424
17. Pearce S.F., Roy P., Nicholson A.C., Hajjar D.P., Febbraio M., and Silverstein R.L. Recombinant glutathione S-transferase/CD36 fusion proteins define an oxidized low density lipoprotein-binding domain. J Biol Chem 273 (1998) 34875-34881
18. Savill J., Hogg N., Ren Y., and Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90 (1992) 1513-1522
19. Navazo M.D., Daviet L., Savill J., Ren Y., Leung L.L., and McGregor J.L. Identification of a domain (155-183) on CD36 implicated in the phagocytosis of apoptotic neutrophils. J Biol Chem 271 (1996) 15381-15385
20. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138 (1997) 707-717
21. Simantov R., Febbraio M., and Silverstein R.L. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24 (2005) 27-34
22. Nicholson A.C., Frieda S., Pearce A., and Silverstein R.L. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 15 (1995) 269-275
23. Boullier A., Gillotte K.L., Horkko S., Green S.R., Friedman P., Dennis E.A., et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 275 (2000) 9163-9169
24. Podrez E.A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 277 (2002) 38503-38516
25. Doi T., Higashino K., Kurihara Y., Wada Y., Miyazaki T., Nakamura H., et al. Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptors. J Biol Chem 268 (1993) 2126-2133
26. Zeng Y., Tao N., Chung K.N., Heuser J.E., and Lublin D.M. Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1. J Biol Chem 278 (2003) 45931-45936
27. Shiffman D., Mikita T., Tai J.T., Wade D.P., Porter J.G., Seilhamer J.J., et al. Large scale gene expression analysis of cholesterol-loaded macrophages. J Biol Chem 275 (2000) 37324-37332
28. Zhao M., Liu Y., Wang X., New L., Han J., and Brunk U.T. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. Apmis 110 (2002) 458-468
29. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
30. Feng J., Han J., Pearce S.F., Silverstein R.L., Gotto Jr. A.M., Hajjar D.P., et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res 41 (2000) 688-696
31. Munteanu A., Taddei M., Tamburini I., Bergamini E., Azzi A., and Zingg J.M. Antagonistic effects of oxidized low density lipoprotein and alpha-tocopherol on CD36 scavenger receptor expression in monocytes: involvement of protein kinase B and peroxisome proliferator-activated receptor-gamma. J Biol Chem 281 (2006) 6489-6497
32. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., and Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 4 (2006) 211-221
33. Lim H.J., Lee S., Lee K.S., Park J.H., Jang Y., Lee E.J., et al. PPARgamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs. Prostaglandins Other Lipid Mediat 80 (2006) 165-174
34. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (2001) 161-171
35. Lipsky R.H., Eckert D.M., Tang Y., and Ockenhouse C.F. The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha. Recept Signal Transduct 7 (1997) 1-11
36. Han C.Y., Park S.Y., and Pak Y.K. Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. Biochem J 350 Pt 3 (2000) 829-837
37. Janabi M., Yamashita S., Hirano K., Sakai N., Hiraoka H., Matsumoto K., et al. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 20 (2000) 1953-1960
38. Wintergerst E.S., Jelk J., Rahner C., and Asmis R. Apoptosis induced by oxidized low density lipoprotein in human monocyte-derived macrophages involves CD36 and activation of caspase-3. Eur J Biochem 267 (2000) 6050-6059
39. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277 (2002) 49982-49988
40. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., and Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268 (1993) 11811-11816
41. Nozaki S., Kashiwagi H., Yamashita S., Nakagawa T., Kostner B., Tomiyama Y., et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 96 (1995) 1859-1865
42. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105 (2000) 1049-1056
43. Febbraio M., Guy E., and Silverstein R.L. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 2333-2338
44. Guy E, Kuchibhotla S, Silverstein R, Febbraio M. Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36 degrees/apoE degrees mice. Atherosclerosis in press.
45. Marleau S., Harb D., Bujold K., Avallone R., Iken K., Wang Y., et al. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 19 (2005) 1869-1871
46. Moore K.J., Kunjathoor V.V., Koehn S.L., Manning J.J., Tseng A.A., Silver J.M., et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 115 (2005) 2192-2201
47. Witztum J.L. You are right too!. J Clin Invest 115 (2005) 2072-2075
48. http://jaxmice.jax.org/services/speedcongenic.html.
49. Moore K.J., and Freeman M.W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 26 (2006) 1702-1711
50. Reardon C.A., Blachowicz L., Lukens J., Nissenbaum M., and Getz G.S. Genetic background selectively influences innominate artery atherosclerosis: immune system deficiency as a probe. Arterioscler Thromb Vasc Biol 23 (2003) 1449-1454
51. http://www.criver.com/flex_content_area/documents/rm_rm_r_pseudomonas_lab_animal.pdf#xml=http://www.criver.com/cgi/texis/search/search/xml.txt?query=pseudomonas&db=criver&id=45af4c501c.
52. Burnett M.S., Gaydos C.A., Madico G.E., Glad S.M., Paigen B., Quinn T.C., et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. J Infect Dis 183 (2001) 226-231
53. Stuart L.M., Deng J., Silver J.M., Takahashi K., Tseng A.A., Hennessy E.J., et al. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol 170 (2005) 477-485
54. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14 (1994) 133-140
55. Zibara K., Chettab K., McGregor B., Poston R., and McGregor J. Increased ICAM-1 and PECAM-1 transcription levels in the heart of Apo-E deficient mice in comparison to wild type (C57BL6). Thromb Haemost 85 (2001) 908-914
56. Zibara K., Chignier E., Covacho C., Poston R., Canard G., Hardy P., et al. Modulation of expression of endothelial intercellular adhesion molecule-1, platelet-endothelial cell adhesion molecule-1, and vascular cell adhesion molecule-1 in aortic arch lesions of apolipoprotein E-deficient compared with wild-type mice. Arterioscler Thromb Vasc Biol 20 (2000) 2288-2296
57. Aslanian A.M., and Charo I.F. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 114 (2006) 583-590
58. Ferreira V., van Dijk K.W., Groen A.K., Vos R.M., van der Kaa J., Gijbels M.J., et al. Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis (2006)
59. Kruth H.S., Jones N.L., Huang W., Zhao B., Ishii I., Chang J., et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J Biol Chem 280 (2005) 2352-2360
60. Yesner L.M., Huh H.Y., Pearce S.F., and Silverstein R.L. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler Thromb Vasc Biol 16 (1996) 1019-1025
61. Huh H.Y., Lo S.K., Yesner L.M., and Silverstein R.L. CD36 induction on human monocytes upon adhesion to tumor necrosis factor-activated endothelial cells. J Biol Chem 270 (1995) 6267-6271
62. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., and Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99 (1997) 2752-2761
63. Li H., Freeman M.W., and Libby P. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest 95 (1995) 122-133
64. Nakagawa T., Nozaki S., Nishida M., Yakub J.M., Tomiyama Y., Nakata A., et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1350-1357
65. Rubic T., and Lorenz R.L. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc Res 69 (2006) 527-535
66. Mallat Z., Heymes C., Ohan J., Faggin E., Leseche G., and Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 19 (1999) 611-616
67. Zhou X., Paulsson G., Stemme S., and Hansson G.K. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 101 (1998) 1717-1725
68. Griffin E., Re A., Hamel N., Fu C., Bush H., McCaffrey T., et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med 7 (2001) 840-846
69. Iwashima Y., Eto M., Hata A., Kaku K., Horiuchi S., Ushikubi F., et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 277 (2000) 368-380
70. Sampson M.J., Davies I.R., Braschi S., Ivory K., and Hughes D.A. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis 167 (2003) 129-134
71. Handberg A., Levin K., Hojlund K., and Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 114 (2006) 1169-1176
72. Liang C.P., Han S., Okamoto H., Carnemolla R., Tabas I., Accili D., et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 113 (2004) 764-773
73. Aitman T.J., Glazier A.M., Wallace C.A., Cooper L.D., Norsworthy P.J., Wahid F.N., et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21 (1999) 76-83
74. Pravenec M., Landa V., Zidek V., Musilova A., Kren V., Kazdova L., et al. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet 27 (2001) 156-158
75. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
76. Han J., Zhou X., Yokoyama T., Hajjar D.P., Gotto Jr. A.M., and Nicholson A.C. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109 (2004) 790-796
77. Puccetti L., Sawamura T., Pasqui A.L., Pastorelli M., Auteri A., and Bruni F. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 35 (2005) 47-51
78. Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T., and Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164 (2002) 179-185
79. Vinals M., Bermudez I., Llaverias G., Alegret M., Sanchez R.M., Vazquez-Carrera M., et al. Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res 66 (2005) 141-149
80. Dressman J., Kincer J., Matveev S.V., Guo L., Greenberg R.N., Guerin T., et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 111 (2003) 389-397
81. Munteanu A., Ricciarelli R., and Zingg J.M. HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol. IUBMB Life 56 (2004) 629-631
82. Pietsch A., Weber C., Goretzki M., Weber P.C., and Lorenz R.L. N-3 but not N-6 fatty acids reduce the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Cell Biochem Funct 13 (1995) 211-216
83. Vallve J.C., Uliaque K., Girona J., Cabre A., Ribalta J., Heras M., et al. Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. Atherosclerosis 164 (2002) 45-56
84. Abumrad N.A. CD36 may determine our desire for dietary fats. J Clin Invest 115 (2005) 2965-2967
85. Laugerette F., Passilly-Degrace P., Patris B., Niot I., Febbraio M., Montmayeur J.P., et al. CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J Clin Invest 115 (2005) 3177-3184
86. Mwaikambo B.R., Sennlaub F., Ong H., Chemtob S., and Hardy P. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest Ophthalmol Visual Sci 47 (2006) 4356-4364
87. Giunta M, Rigamonti AE, Scarpini E, Galimberti D, Bonomo SM, Venturelli E, et al. The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006.
88. Hoebe K., Georgel P., Rutschmann S., Du X., Mudd S., Crozat K., et al. CD36 is a sensor of diacylglycerides. Nature 433 (2005) 523-527
89. Hirano K., Kuwasako T., Nakagawa-Toyama Y., Janabi M., Yamashita S., and Matsuzawa Y. Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med 13 (2003) 136-141
90. Yamashita S, Hirano KI, Kuwasako T, Janabi M, Toyama Y, Ishigami M, et al. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem in press.